Diagnostic and prognostic tests in systemic lupus erythematosus

Natalia Vasquez-Canizares; Dawn Wahezi; Chaim Putterman

doi:10.1016/j.berh.2017.10.002

Diagnostic and prognostic tests in systemic lupus erythematosus

Natalia Vasquez-Canizares, Dawn Wahezi, Chaim Putterman

Research output: Contribution to journal › Review article › peer-review

26 Scopus citations

Abstract

Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disease characterized by autoantibodies directed against numerous self-nuclear antigens. Because of the heterogeneous nature of lupus, it has been challenging to identify markers that are sensitive and specific enough for its diagnosis and monitoring. However, with the sequencing of the human genome, rapid development of high-throughput approaches has allowed for a better understanding of the etiopathogenesis of complex diseases, including SLE. Here we present a review of the latest advancements in biomarker discovery during the “omics” era, using these novel technologies, for assisting in the diagnosis and prognosis of patients with SLE.

Original language	English
Pages (from-to)	351-363
Number of pages	13
Journal	Best Practice and Research: Clinical Rheumatology
Volume	31
Issue number	3
DOIs	https://doi.org/10.1016/j.berh.2017.10.002
State	Published - Jun 2017
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2017 Elsevier Ltd

Funding

Funders	Funder number
National Institute of Arthritis and Musculoskeletal and Skin Diseases	R01AR065594

Keywords

Biomarkers
Epigenetics
Genomics
Lupus nephritis
Metabolomics
Proteomics
Systemic lupus erythematosus
Transcriptomics

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.berh.2017.10.002

Cite this

@article{2d6cd926435d4933b02381fd769075ff,

title = "Diagnostic and prognostic tests in systemic lupus erythematosus",

abstract = "Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disease characterized by autoantibodies directed against numerous self-nuclear antigens. Because of the heterogeneous nature of lupus, it has been challenging to identify markers that are sensitive and specific enough for its diagnosis and monitoring. However, with the sequencing of the human genome, rapid development of high-throughput approaches has allowed for a better understanding of the etiopathogenesis of complex diseases, including SLE. Here we present a review of the latest advancements in biomarker discovery during the “omics” era, using these novel technologies, for assisting in the diagnosis and prognosis of patients with SLE.",

keywords = "Biomarkers, Epigenetics, Genomics, Lupus nephritis, Metabolomics, Proteomics, Systemic lupus erythematosus, Transcriptomics",

author = "Natalia Vasquez-Canizares and Dawn Wahezi and Chaim Putterman",

note = "Publisher Copyright: {\textcopyright} 2017 Elsevier Ltd",

year = "2017",

month = jun,

doi = "10.1016/j.berh.2017.10.002",

language = "אנגלית",

volume = "31",

pages = "351--363",

journal = "Best Practice and Research: Clinical Rheumatology",

issn = "1521-6942",

publisher = "Bailliere Tindall Ltd",

number = "3",

}

TY - JOUR

T1 - Diagnostic and prognostic tests in systemic lupus erythematosus

AU - Vasquez-Canizares, Natalia

AU - Wahezi, Dawn

AU - Putterman, Chaim

PY - 2017/6

Y1 - 2017/6

N2 - Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disease characterized by autoantibodies directed against numerous self-nuclear antigens. Because of the heterogeneous nature of lupus, it has been challenging to identify markers that are sensitive and specific enough for its diagnosis and monitoring. However, with the sequencing of the human genome, rapid development of high-throughput approaches has allowed for a better understanding of the etiopathogenesis of complex diseases, including SLE. Here we present a review of the latest advancements in biomarker discovery during the “omics” era, using these novel technologies, for assisting in the diagnosis and prognosis of patients with SLE.

AB - Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disease characterized by autoantibodies directed against numerous self-nuclear antigens. Because of the heterogeneous nature of lupus, it has been challenging to identify markers that are sensitive and specific enough for its diagnosis and monitoring. However, with the sequencing of the human genome, rapid development of high-throughput approaches has allowed for a better understanding of the etiopathogenesis of complex diseases, including SLE. Here we present a review of the latest advancements in biomarker discovery during the “omics” era, using these novel technologies, for assisting in the diagnosis and prognosis of patients with SLE.

KW - Biomarkers

KW - Epigenetics

KW - Genomics

KW - Lupus nephritis

KW - Metabolomics

KW - Proteomics

KW - Systemic lupus erythematosus

KW - Transcriptomics

UR - http://www.scopus.com/inward/record.url?scp=85033241707&partnerID=8YFLogxK

U2 - 10.1016/j.berh.2017.10.002

DO - 10.1016/j.berh.2017.10.002

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???

C2 - 29224677

AN - SCOPUS:85033241707

SN - 1521-6942

VL - 31

SP - 351

EP - 363

JO - Best Practice and Research: Clinical Rheumatology

JF - Best Practice and Research: Clinical Rheumatology

IS - 3

ER -

Diagnostic and prognostic tests in systemic lupus erythematosus

Abstract

Bibliographical note

Funding

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this